About us

At SmartPharm Therapeutics, we are committed to an ambitious goal: to make biologic therapies accessible for the patients who need them. We seek to accomplish this goal by developing gene encoded therapeutics capable of generating therapeutic proteins inside the patient’s body—”biologics from within.”

SmartPharm was formed in 2017 to catalyze a unique network of technologies and development partners in order to pursue high-impact opportunities in key medical markets.

Jose Trevejo, MD, PhD

“We believe that the coming decades will be the age of gene therapy in medicine. Our company’s role is to create gene-based drugs that can make desired therapeutics in the patient’s own body. We believe this revolutionary approach to biologics will make it possible to provide biologic therapies for the patients that need them.”

Management Team

José Trevejo, MD, PhD
José Trevejo, MD, PhDCEO and President

Dr. Trevejo brings his experience and passion for leading research and development teams in the advancement of novel therapeutics for serious diseases. Before joining SmartPharm as CEO, Dr. Trevejo served as vice president, clinical development at Cyclerion Therapeutics, where he helped advance a diverse clinical pipeline in rare diseases such as sickle cell anemia. Dr. Trevejo joined Ironwood/Cyclerion from Visterra, where he was a member of the executive team and lead the pre-clinical and clinical development of novel biologics. While at Visterra, he oversaw the transition to a clinical stage company as well as helped to secure a $215 million DHHS award to support development of a novel treatment for influenza. Prior to Visterra, he held clinical development leadership positions at Genentech and Vertex Pharmaceuticals. Before entering the biotechnology industry, he served as instructor in medicine at Harvard Medical School and was a principal biomedical scientist at the Draper Laboratory. Dr. Trevejo completed his clinical training at BWH/BIDMC/Harvard Medical School and earned his MD and PhD degrees from the Tri-Institutional MD-PhD program at Cornell-Rockefeller-Sloan Kettering in New York.
Timothy Brauns, MBA
Timothy Brauns, MBAChief Operating Officer

Mr. Brauns brings tested and diverse operational experience in the life sciences field over the last 25 years gained in the academic hospital environment and in biotech and medical device companies and medical philanthropies. Prior to joining SmartPharm, Mr. Brauns was the associate director of the Vaccine and Immunotherapy Center (VIC) at the Massachusetts General Hospital (MGH), where over a five-year period he helped to double the funding of the center, including landing key STTR grants and other contracts for support of preclinical life science technologies and guiding four preclinical technologies toward development partnerships. Before his work with VIC, he held positions as vice president of strategic planning for Boston BioCom, a biotechnology company; vice president of marketing and communication for BL Healthcare, a home health monitoring technology company; assistant director of the international program in the Center for the Integration of Medicine and Innovative Technology (CIMIT) at MGH; and director of program development at the Adelson Medical Research Foundation. Mr. Brauns brings special skills in the development and management of “distributed development” of new life science technologies through cross-disciplinary, inter-institutional, industry-academic teams, and in sponsored program developing, assisting organizations he was part of in securing over $60 million in grants and contracts from a broad range of federal and private funding organizations.